Company news

Quest PharmaTech Inc. news in 2016

Quest PharmaTech Inc.'s news releases, calls and decks from 2016, newest first.

View company

OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer

December 7, 2016

OncoQuest Announces Positive Interim Results from Its Phase 2b Clinical Study

November 29, 2016

Bellus Skin Rejuvenation Serum: Quest PharmaTech Launches Scientifically Proven, Clinically Validated Premium Skin Care Cosmetics in Canada

November 14, 2016

OncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cancer

November 2, 2016

Quest PharmaTech Inc. Announces Change of Auditor

October 28, 2016

Anti-MUC1 MAb AR20.5 Induces Specific Cell Mediated Immune Response to MUC1 Antigen in Pre-Clinical Pancreatic Cancer Model

October 20, 2016

Quest PharmaTech Inc. Amends Warrant Terms

September 16, 2016

/C O R R E C T I O N from Source -- Quest PharmaTech Inc./

September 6, 2016

Quest PharmaTech Announces Filing of Restated Audited Financial Statements for the Year Ended January 31, 2016 and for the Quarter Ended April 30, 2016

August 5, 2016

Quest PharmaTech's Subsidiary, OncoQuest, Signs Agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. to Fund Immunotherapy for Treatment of Cancer in China

March 22, 2016

Decks in 2016